Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00634231 : A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
PhasePhase 1
AgesMin: 3 Years Max: 21 Years
Eligibility
Inclusion Criteria:

- Patients must be 3 years of age or older

- Patients must be planning to undergo standard of care treatment with surgery and
radiation therapy.

- Patients must have malignant glioma or recurrent ependymoma

- Tumor must be accessible for injection and must not be located in the brainstem or
deep midbrain

- Performance Score: Karnofsky ?60% if >10y/o, Lansky ?60 if ?10y/o

- Bone Marrow Function: Patients must have adequate bone marrow function defined as a
peripheral absolute neutrophil count ? 1000/µl, platelet count ? 100,000/µl
(transfusion independent) and hemoglobin ? 8.0 gm/dL

- Renal Function: Patients must have serum creatinine ? 1.5 times upper limit of
institutional normal for age and/or GFR ? 70 mL/min/1.73 m2.

- Hepatic Function: Bilirubin ? 1.5 times institutional normal; SGPT (ALT) < 3 times
institutional normal

- Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked
prior to enrollment and clinically significant abnormalities corrected prior to
surgery/AdV-tk injection

- Patients with seizure disorder may be enrolled if well controlled

- Signed informed consent according to institutional guidelines must be obtained

Exclusion Criteria:

- Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection
but not to exclude patients with a distant history of resolved hepatitis A infection

- Patients on immunosuppressive drugs (with exception of corticosteroid)

- Known history of HIV or underlying immunodeficiency

- Patients with acute infections (viral, bacterial or fungal infections requiring
therapy)

- Pregnant or breast-feeding patients. Female patients of childbearing age must have
negative serum or urine pregnancy test within 1 week of beginning therapy

- Other serious co-morbid illness or compromised organ function

- No other investigational anti-tumor agents within 30 days prior to study entry or
during active participation in the study (defined as from study entry until tumor
progression)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00634231      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740